Free Trial

Pharming Group (PHAR) Competitors

Pharming Group logo
$10.20 +0.11 (+1.04%)
As of 01:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PHAR vs. ALVO, MIRM, CPRX, GMTX, AMRX, NAMS, RARE, OGN, APLS, and IBRX

Should you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Alvotech (ALVO), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), Gemini Therapeutics (GMTX), Amneal Pharmaceuticals (AMRX), NewAmsterdam Pharma (NAMS), Ultragenyx Pharmaceutical (RARE), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.

Pharming Group vs. Its Competitors

Alvotech (NASDAQ:ALVO) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

Alvotech has a net margin of 16.42% compared to Pharming Group's net margin of -4.14%. Pharming Group's return on equity of -6.01% beat Alvotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Alvotech16.42% -36.37% 12.70%
Pharming Group -4.14%-6.01%-3.23%

0.0% of Pharming Group shares are owned by institutional investors. 0.5% of Alvotech shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Alvotech has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, Pharming Group has a beta of 0.02, meaning that its stock price is 98% less volatile than the S&P 500.

Alvotech presently has a consensus price target of $16.00, indicating a potential upside of 74.10%. Pharming Group has a consensus price target of $30.00, indicating a potential upside of 193.97%. Given Pharming Group's higher possible upside, analysts plainly believe Pharming Group is more favorable than Alvotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alvotech
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Pharming Group
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Pharming Group has lower revenue, but higher earnings than Alvotech. Pharming Group is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$491.98M5.63-$231.86M$0.3724.84
Pharming Group$297.20M2.35-$11.84M-$0.20-51.03

In the previous week, Alvotech had 4 more articles in the media than Pharming Group. MarketBeat recorded 7 mentions for Alvotech and 3 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.07 beat Alvotech's score of 0.21 indicating that Pharming Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alvotech
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Pharming Group
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Alvotech beats Pharming Group on 8 of the 15 factors compared between the two stocks.

Get Pharming Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PHAR vs. The Competition

MetricPharming GroupMED IndustryMedical SectorNASDAQ Exchange
Market Cap$699.15M$3.07B$5.68B$9.50B
Dividend YieldN/A2.44%4.05%3.99%
P/E Ratio-51.0220.8227.9220.01
Price / Sales2.35249.55396.7382.92
Price / Cash132.2041.9636.1958.45
Price / Book3.148.328.665.83
Net Income-$11.84M-$55.19M$3.24B$258.22M
7 Day Performance-1.02%5.31%3.38%2.18%
1 Month Performance-7.73%17.91%10.91%12.26%
1 Year Performance20.20%7.33%35.23%21.18%

Pharming Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PHAR
Pharming Group
2.3939 of 5 stars
$10.21
+1.0%
$30.00
+194.0%
+15.2%$699.15M$297.20M-51.02280Positive News
Upcoming Earnings
Gap Down
ALVO
Alvotech
2.8817 of 5 stars
$8.64
+0.1%
$16.00
+85.2%
-22.4%$2.60B$491.98M23.351,032
MIRM
Mirum Pharmaceuticals
3.3979 of 5 stars
$51.95
+0.0%
$65.50
+26.1%
+32.0%$2.57B$336.89M-32.27140
CPRX
Catalyst Pharmaceuticals
4.9167 of 5 stars
$21.01
-0.1%
$32.83
+56.3%
+22.8%$2.57B$491.73M13.3880News Coverage
Positive News
GMTX
Gemini Therapeutics
N/A$57.77
0.0%
N/A+32.2%$2.50BN/A-57.7730High Trading Volume
AMRX
Amneal Pharmaceuticals
3.3061 of 5 stars
$7.91
-0.8%
$11.60
+46.6%
+8.6%$2.50B$2.83B-197.708,100
NAMS
NewAmsterdam Pharma
3.64 of 5 stars
$22.56
+1.6%
$41.30
+83.1%
+26.6%$2.49B$45.56M-12.004
RARE
Ultragenyx Pharmaceutical
4.3633 of 5 stars
$26.39
+0.3%
$83.64
+216.9%
-38.0%$2.49B$560.23M-4.491,294Upcoming Earnings
Gap Down
High Trading Volume
OGN
Organon & Co.
4.8619 of 5 stars
$9.43
-0.4%
$18.00
+91.0%
-53.0%$2.46B$6.40B3.274,000
APLS
Apellis Pharmaceuticals
4.3371 of 5 stars
$19.28
-1.0%
$40.00
+107.5%
-46.0%$2.45B$781.37M-10.77770Upcoming Earnings
IBRX
ImmunityBio
1.9946 of 5 stars
$2.68
-2.5%
$12.25
+357.1%
-47.1%$2.43B$14.74M-4.62590

Related Companies and Tools


This page (NASDAQ:PHAR) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners